arrow
M

Mariella Spalato Ceruso

medicine
H指数:17
被引数:1,076

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical presentation, management and outcome of 11,132 patients with liposarcoma patients: a population-based study from the NETSARC+ registry

临床表现、治疗管理及结局:11,132例脂肪肉瘤患者的流行病学研究(基于NETSARC+登记系统)

2025-07-310
PREAI
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab

用抗血管生成药物重塑冷软组织肉瘤的肿瘤微环境: regorafenib联合avelumab的2期试验

2025-06-270
OA
Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial☆

瑞戈非尼作为一线多柔比星类化疗后的维持疗法在进展期非脂肪源性软组织肉瘤患者中的应用:一项双盲随机试验☆

2025-04-080
PRE
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

6年与3年伊马替尼辅助治疗局部GIST复发风险高的患者的随机研究

2024-12-016
OAAI
EREMISS trial: A double-blind placebo (PBO)- controlled randomised trial assessing efficacy/safety of regorafenib (REGO) as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma (ASTS) patients (pts)

EREMISS试验:一项双盲安慰剂(PBO)对照的随机试验,评估regorafenib(REGO)作为维持疗法在经过一线多柔比星为基础的化疗后的晚期软组织肉瘤(ASTS)患者(pts)中的疗效/安全性。

2024-09-010
PRE
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study
2023-11-044
OAAI
Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
2022-10-279
OAAI